Vancouver, British Columbia (PRWEB) May 27, 2013
Ondine Biomedical Inc. announces that Dr. Titus Wong of the Vancouver General Hospital, will be speaking at the World Congress of the International Photodynamic Association (IPA) on May 28th through May 31st, 2013. Dr. Wong will be describing the protocols and benefits of Photodisinfection. Dr. Wong and his team were recently awarded the inaugural John Conly Innovation award at the 2012 AMMI-CACMID conference, recognizing a novel and creative strategy to improve patient safety and public health in Canada.
With growing worldwide recognition, MRSAid™ Photodisinfection System has become one of the most valuable technologies available in preventing surgery-related infections. Photodisinfection is a broad spectrum antimicrobial topical therapy that has been proven for decades to instantly and safely eliminate harmful pathogens such as antibiotic resistant superbugs. Vancouver General Hospital's use of MRSAid's innovative universal pre-surgical protocol resulted in a 39% reduction in surgical site infections and $1.9 million in cost savings.
The IPA World Congress is a biannual conference highlighting the advances in scientific and clinical research around the world. This year's Congress is being held May 28th to May 31st, 2013 at the Ritz-Carlton Hotel, Seoul, Korea. Global leaders in the field of PDT and their work will be represented during this event. Clinicians, scientists, researchers, hospital administrators, students are welcome to participate at this year's conference.
The IPA was founded in 1986 and its membership consists of the most prominent international clinicians and scientists involved in performing and researching photodynamic therapy (PDT) and photodiagnosis (PD). The purpose of the IPA is to promote the study of diagnosis and treatment using light and photosensitisers, to disseminate such information to the members of the IPA, the medical community and to the general public. The IPA organises an International Congress every two years to highlight leading research activities in the clinical and basic research aspects of PDT.
About Ondine Biomedical Inc.
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with Research and Development laboratories in Bothell, Washington, USA and Minneapolis, Minnesota. Please visit the Company's website at: http://www.ondinebio.com and http://www.ondineblog.com. For further information please contact us at: Ondine Biomedical Inc. info(at)ondinebio(dot)com.
Read the full story at http://www.prweb.com/releases/Titus_Wong/Photodisinfection/prweb10771904.htm.
Copyright©2012 Vocus, Inc.
All rights reserved